The endocannabinoid system as a target for the treatment of motor dysfunction.
about
The endocannabinoid system in normal and pathological brain ageingIs lipid signaling through cannabinoid 2 receptors part of a protective system?Cannabis in the Treatment of Dystonia, Dyskinesias, and TicsRegulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice.Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety.In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liabilityNeurological soft signs in Tunisian patients with first-episode psychosis and relation with cannabis useAre cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insultsCannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choiceMetabolic syndrome as a risk factor for neurological disorders.Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disordersTemporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats.CB(1) cannabinoid receptors and their associated proteins.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionNew insights on endocannabinoid transmission in psychomotor disorders.Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.Endocannabinoids in striatal plasticity.Modulating the endocannabinoid system in human health and disease--successes and failuresStriatal CB1 and D2 receptors regulate expression of each other, CRIP1A and δ opioid systems.Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.Adenosine receptors: expression, function and regulation.Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.Dopamine and glutamate in Huntington's disease: A balancing act.The multiplicity of action of cannabinoids: implications for treating neurodegeneration.Huntington's disease and Group I metabotropic glutamate receptors.Prospects for cannabinoid therapies in basal ganglia disorders.Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?Endocannabinoid modulation of dopaminergic motor circuits.The influence of cannabinoids on generic traits of neurodegeneration.A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation.A Single Intrathecal or Intraperitoneal Injection of CB2 Receptor Agonist Attenuates Bone Cancer Pain and Induces a Time-Dependent Modification of GRK2.Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.Pharmacogenetics of tardive dyskinesia: an updated review of the literature.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?
P2860
Q22242668-F6F2A882-F754-4F18-9112-3E93B068C53EQ24633122-E1A259EA-381A-4627-BB2C-184FBE4C1839Q27336419-2DCF31B5-BF70-4350-B1CA-4478706AD7F7Q30410119-C648B7ED-F4AD-47DF-8968-D5A62EE84475Q30596478-BD84F702-FCA0-4979-B90F-9FD1CC548332Q33751118-860F236A-716C-42AF-BABB-520F86707046Q33901507-04DA95C9-ABBC-49F9-9ECD-8646E4569954Q33976751-671DC0B2-190D-4845-9302-85C7490DB40EQ34009116-077D3834-5FC0-48C1-9056-492464274CD1Q34053352-D80B0425-09C0-4741-9EFD-0757A1D6C8BEQ34224030-1B920FD5-18CB-4A07-A951-95F162700AD3Q34391577-170B9B01-167A-45CF-B202-681507E5384EQ35014951-21EBADCB-0F90-42C0-91CB-0E5EA6F49A0EQ35232109-11FB9479-7DFB-45C1-89B3-CE81790D831BQ35499568-6BA50BF6-D535-4762-9F7F-2B5ECF602BABQ36074595-EE9E0CFF-7898-40D8-9209-22C165AF45D4Q36155898-E00FDCE5-5F21-45B1-AEB3-BD921FDD5ED2Q36686382-147569A1-A5D2-4B9A-924A-98F993178FB6Q36933683-0698A478-8717-42C3-90F5-9B656562E656Q36972027-885DBB14-1351-48F6-8B23-238D43FDBC7FQ36975938-B1C84C1D-EFAD-4C84-902F-D44F411FB943Q37512670-D3B8033A-DCB6-4C0F-B697-AA0EF96729F7Q37637769-391FF098-E7D1-429A-94CE-FF4B0AA69ACEQ37645138-80798653-FC49-4F5B-BD1C-D0452C043451Q37659341-B18EA0EF-0FA3-4420-9955-E5C88B133DFAQ37734563-2157D267-FF33-4E27-A296-6C49FBDEBC96Q37793366-3BDF855F-8CC5-4146-9829-D294412693E4Q37820343-20D4E85C-4D64-453E-B3EB-754F2664BF9BQ37872326-3F9D25B7-37B4-47A1-A541-BF02789907E7Q38012845-8E4E29CC-399D-429C-8198-2EC92DD0D173Q38018946-F0B4821C-B1D9-435F-A830-23559188E0A6Q38156518-E24F29B7-77E8-49B0-9FD9-ED3CF4AD7DA6Q38392800-ADA30F49-7724-4B6A-BA00-6E98358C0143Q38522769-A7CA18E4-7A3F-460C-BE00-576A6F99A1F0Q38563981-B2DEDC1A-A8F7-494F-9FE7-211C069059E7Q38684679-93EE3357-C8D0-4EA0-9E9B-B1F318EE8DCEQ38789599-E0798F47-4207-467F-B3FB-C7DE7D4A13C9Q38809361-9C5C326B-D2EA-4C54-9430-D80062AA44A9Q38911685-FCADB5F6-8DFC-4A55-9AE7-2B97C373EDDFQ38951947-6B989D14-EDCE-4015-94DD-128C7FA008E4
P2860
The endocannabinoid system as a target for the treatment of motor dysfunction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The endocannabinoid system as a target for the treatment of motor dysfunction.
@en
The endocannabinoid system as a target for the treatment of motor dysfunction.
@nl
type
label
The endocannabinoid system as a target for the treatment of motor dysfunction.
@en
The endocannabinoid system as a target for the treatment of motor dysfunction.
@nl
prefLabel
The endocannabinoid system as a target for the treatment of motor dysfunction.
@en
The endocannabinoid system as a target for the treatment of motor dysfunction.
@nl
P2860
P1476
The endocannabinoid system as a target for the treatment of motor dysfunction.
@en
P2093
Javier Fernández-Ruiz
P2860
P304
P356
10.1111/J.1476-5381.2008.00088.X
P407
P577
2009-02-13T00:00:00Z